Strainsforpains, Inc. Sets the Stage for Massive Growth in the Cannabis Industry and AI Innovation
Rhea-AI Summary
Strainsforpains (OTC: EBYH) reported significant growth in 2024 with over $300,000 in CBD sales and projects reaching $2 million in sales by end of 2025. The company operates from a 7-acre facility in Pennsylvania, strategically located near Amazon's $650 million AI data center grid.
The company is expanding through multiple initiatives including: new CBD formulations with Australian plum extract, planned collaborations with influencers and athletes, and development of an AI-powered app for healthcare professionals. The company maintains research partnerships with institutions like Harvard, Mt. Sinai, and Johns Hopkins, and has established joint ventures with Cannabis Science Inc., GenBio, and Cannasphere Biotech for drug development and CBD product innovation.
Additional growth plans for 2025 include launching a podcast and TV show across major streaming platforms, and the CEO's upcoming book release on cannabis and pain management in February 2025.
Positive
- Achieved $300,000 in CBD sales in 2024
- Projects $2 million in CBD sales for 2025
- Strategic location near Amazon's $650 million AI data center
- Multiple research partnerships with major institutions
- Joint ventures with established cannabis/biotech companies
Negative
- Current revenue scale is relatively small
- Many initiatives are still in planning phase without proven results
News Market Reaction 1 Alert
On the day this news was published, EBYH gained 3.70%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Strainsforpains, Inc. fka/ E-Buy Home, Inc. (OTC: EBYH). Strainsforpains, Inc. is redefining the future of wellness, cannabis innovation, and AI integration. With a transformative year in the books, the company is poised to disrupt multiple industries and deliver groundbreaking results in 2025.
Unparalleled Revenue Growth and Market Expansion
"2024 was a milestone year," stated CEO Y. Simon Shainberg. "Our revenues far surpassed expectations, with over
Strainsforpains is aggressively expanding its product lines and geographic reach, bringing innovative CBD solutions to a wider audience. New formulations featuring powerful antioxidants like Australian plum extract promise to elevate the company’s reputation as a leader in health and wellness solutions.
A Prime Location for Innovation
Strategically positioned within Amazon’s
Influencer-Driven Marketing and Endorsements
2025 will see Strainsforpains collaborating with high-profile influencers, athletes, and celebrities to bring its products to the forefront of the market. These partnerships will drive brand visibility, credibility, and consumer engagement across global markets.
Pioneering Cannabis Research and AI Integration
Building on over 20 years of research and collaborations with prestigious institutions such as Harvard, Mt. Sinai, and Johns Hopkins, Strainsforpains is at the forefront of cannabinoid science. The company’s proprietary app, powered by advanced AI algorithms, provides real-time data to healthcare professionals, revolutionizing pain management and patient care.
"We’re blending cutting-edge cannabis research with state-of-the-art AI to improve lives and establish ourselves as leaders in both the medical and tech industries," Shainberg added.
Media and Thought Leadership
Strainsforpains is also making waves in the media with plans for a podcast and TV show in 2025. These platforms will feature expert insights, celebrity endorsements, and compelling stories about the transformative power of cannabis. The podcasts will stream on major platforms like Roku, YouTube, Facebook, and Instagram, amplifying the company’s global reach.
Adding to the momentum, Mr. Shainberg’s upcoming book on cannabis and pain management will debut in February 2025, further cementing Strainsforpains as a thought leader in the wellness industry.
Strategic Partnerships for Long-Term Growth
Our company has several high-impact collaborations that will enhance its overall growth. We have a joint venture with Cannabis Science, Inc. on commercialization and drug development for their Harvard studied and patented cancer killing drugs utilizing cannabinoids. We are proud to have established strong partnerships with Virginia and Pennsylvania farmers and distributors ensuring a resilient and optimized supply chain, with products stored both at our 7-acre Pennsylvania facility and our New York City location. We have a licensing arrangement with GenBio, a biotech research company, whose mission is to develop the next generation of anti-inflammatory drugs. We have a project with Cannasphere Biotech, LLC, an Arizona based leading manufacturer of CBD products, to develop water solubility and nanoliposomal cannabinoid products. All our partnerships and agreements are with companies that have robust proprietary intellectual property, expertise in the cannabis space, and have developed industry relationships. These partnerships enhance its supply chain, innovation pipeline, and market presence.
A Visionary Future
Positioned at the crossroads of wellness and technology, Strainsforpains is set to redefine the cannabis and AI landscapes. With bold plans, strategic alliances, and a relentless commitment to innovation, the company is crafting a compelling growth story that investors won’t want to miss.
Stay tuned for upcoming announcements as Strainsforpains continues to break barriers and shape the future of wellness and data-driven healthcare.
Management and Advisory
Mr. Simon Shainberg has over 17 years of cannabis research and studies within the wellness space, including working with Raphael Mechoulam of Tel Aviv, the well known originator of the concept of the cannabinoid system. He has extensive experience in algorithmic methodology, healthcare technology, pain management, artificial intelligence, and mergers and acquisitions. He is a member of the prestigious International Cannabinoid Research Society, https://icrs.com
Dr. Michael Stern is a board certified urologist and urological surgeon. He served on the faculty at Bast-yr University School of Naturopathic Medicine for 11 years ( 1995-2006). Dr. Stern operated the Northwest healthy Options Clinic in Seattle, Washington. He continues to advise patients on lifestyle issues and alternative healthy treatments for a wide variety of diseases, including the use of medical cannabis. He is also known for his diet book “The Rotation Diet”.
Mr. Epstein is based in New York City. He is the President and Founder of Geoval Consulting LLC, a firm that applies geological expertise and experience to evaluate prime target investment opportunities. Geoval utilizes geochemical analytical data and modeling for risk profiling to certify geological assets and property selection for private and public entities. He has over 50 publications, including work on experimental and field biogeochemical reactions in saltwater in respected scientific journals, with a focus on successfully merging geology with economic viability. For over 30 years, Samuel Epstein served as an investment advisor as an SVP for Merrill Lynch and Morgan Stanley. For the past 20 years, serves on the Board of Governors for Touro College and University, and acting as an executive director of the Touro College Center for Environmental and Geological Research.
About Strainsforpains, Inc., (OTC: EBYH) fka/ E-Buy Home Inc.
Strainsforpains is progressing towards completing its Audit to become fully-reporting, change its symbol, creating the revenues and asset base for a NASDAQ Uplisting. Strainsforpains, Inc. is an innovative healthcare data technology Company located in New York, N.Y. The Company’s objectives are to provide doctors, nurses, dispensaries, and patients access to an APP that will allow for an advanced determination of comparison of strains or brands of cannabis combinations with major illnesses, in a user-friendly manner. Furthermore, the proprietary app incorporating advanced artificial intelligence, collaborating with pain management departments at hospitals and health care professionals. The app integrates artificial intelligence to expand the selection of cannabis varietals, positioning itself as a leading educational tool for pain management operations at hospitals and with doctors specializing in pain relief. The company owns a 7 acre facility in Pennsylvania. Mr. Shainberg is a member of the prestigious International Cannabinoid Research Society, https://icrs.co/.
Safe Harbor Statement
Statements in this press release that are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although Strainsforpains, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Strainsforpains, Inc. is unable to give any assurance that its expectations will be attained. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Strainsforpains, Inc.’s ability to control, and those actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in Strainsforpains, Inc. filings with the Securities and Exchange Commission and OTC Markets.
For further info and Media Contact: Y. Simon Shainberg, CEO
1-347-218-0844
simon@strainsforpains.com
https://www.strainsforpains.com/
https://www.facebook.com/profile.php?id=100071016855607
https://twitter.com/strainsforpains https://www.instagram.com/strains_for_pains/
https://www.instagram.com/strains_for_pains/
https://www.linkedin.com/company/strainsforpains/?viewAsMember=true
https://audioboom.com/posts/8466160-strainsforpains-inc-discusses-inspiration-apptechnology-and-cbd-market-entrance-with-the-stoc
https://www.youtube.com/watch?v=E-lftNrcFLk
FAQ
What were EBYH's CBD sales in 2024 and what is projected for 2025?
Where is EBYH's main facility located and why is it significant?
What key partnerships does EBYH have for cannabis research and development?
What new products and initiatives is EBYH launching in 2025?
